Tempus xF+ Liquid Biopsy Assay

Tempus is proud to offer one of the largest available liquid biopsy (LBx) panels on the global market. The panel interrogates 523 genes focused on oncogenic and resistance mutations in cell-free DNA (cfDNA) to help identify therapy opportunities.

  • Depth of Sequencing (Avg.)

    DNA sequencing is performed to >5,000x and >1,500x unique coverage for enhanced and additional regions, respectively.

  • Platforms Used

    Illumina NovaSeq

  • Accepted Sample Types

    Peripheral blood

  • Alterations Identified

    SNV, insertions / deletions, CNVs, gene rearrangements from select genes, MSI, bTMB

  • Sensitivity

    >90% for SNVs (≥ 0.25% VAF), >95% for indels (≥ 1% VAF), 84% CNVs, 100% translocations, 90% for MSI-H, 79% for bTMB1

enhanced testing

Discover actionable alterations with complementary testing

Non-overlapping actionable gene alterations may be discovered using complementary tissue and liquid biopsies. In one study of NSCLC patients, the addition of plasma sequencing increased targetable mutation detection to 35.8% compared to 20.5% with tissue alone.2

image description


Monitor disease recurrence after treatment

Longitudinal testing can help in the identification of genomic alterations predictive of response and resistance to targeted therapies and evaluation of genomic heterogeneity.

image description
  1. Tempus xF+ validation paper. Download here.
  2. In a subset of 229 NSCLC patients, tissue testing alone detected targetable mutations for 47 patients, whereas plasma sequencing increased targetable mutation detection to 82. Aggarwal C et al. Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non–Small Cell Lung Cancer. JAMA Oncol. 2019;5(2):173–180. doi:10.1001/jamaoncol.2018.4305

Interested in learning more about our liquid biopsy offering?

Contact us today.